Denny Lanfear, Coherus BioSciences CEO
January 10, 2023 04:24 PM ESTUpdated January 12, 10:51 AM
Deals

Co­herus pays out $32M for ex­clu­sive US com­mer­cial­iza­tion rights to Eylea biosim­i­lar

Paul Schloesser

Associate Editor

Co­herus Bio­Sciences is adding to its pipeline, this time grab­bing com­mer­cial­iza­tion rights for a biosim­i­lar of one of the largest oph­thal­mol­o­gy drugs on the mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times